A first-time-in-human single ascending dose trial of TRV250 for the treatment of acute migraine
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs TRV 250 (Primary) ; TRV 250 (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man; Pharmacokinetics
- 12 Dec 2019 According to a Trevena Media Release, data from this study was presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), in Orlando, FL.
- 12 Dec 2019 Results published in the Trevena Media Release
- 28 Jun 2018 Status changed from active, no longer recruiting to completed, according to a Trevena media release.